When the Peer reviewed white paper comes out on VGX-3100 and validates their platform and technology, this stock will open at $300+. What are the shorts going to do when any stock they short, instituions and hedgefunds will be buying with abandon.
The Peer reviewed white paper on VGX 3100 I believe will validate their whole platform. When that happens than we will see a buyout for $20 Billion from a Novartis, Roche or Merck.
Tasimelteon is on the agenda, however I believe they address different issues each time leading up to formal approval. We will have to see what the minutes bare next week. I would be surprised to see if it got approved this month. GL
Harvard after pressure from students has agreed to divest in all fossil fuel stocks. It sounds like they will find or look at green investments. This could be a big shot in the arm if they invest in SUNE.
Its typical of Wallstreet and the valuations that they place on stocks. Just like ETSY and Shake Shack, however our time will come, and it will be sooner than later.
I view this as a positive, since it is not really going down a lot. It is consolidation for the next big leg up. Let them short all they want.
You are making it like they are using a taser. This is the furthest from the truth. It is less invasive than Electro shock therapy. You sound very knowledgable, but you have muddied the facts which is what most shorts tend to do. However you at least try to engage with the longs in an intelligent conversation. I will give you that much. Keep shorting and we will see what happens in the long run. GL
It never ceases to amaze me the sheer stupidity that people compare INO's technology to needle free injections. It shows how little these shorts know about their technology and all of their patents.. To hear people about dilution to initiate a phase III study.. The peer revied white paper that will be coming out shortly can make this stock go to $50 if it validates the platform. They can sell 10 million shares at 50 and be rock solid financially until VGX-3100 gets FDA approval.
You I know I read this article this morning and I thought it was stating the obious, that every small biotech company goes through. In fact they used to say that about Amgen and Genentech. Amgen came pretty close until J&J threw them a life line, that benefitted both companies greatly through the years.
Stock is around $65, and Zack's is saying people may miss the boat on this one. They have a technology platform that is broad like INO. However I do not think they are a better company, so should INO be around $65-100?
Sentiment: Strong Buy
We will see very shortly how scared you are, and most likely you will just disappear under your current name, and use a new name like barbossaasanahole and say you are long INO